Clinical trials
T-cell Leukemia clinical trials
Below are recruiting t-cell leukemia clinical trials, each written for real people, not researchers. We’re tracking 189 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01676805Recruiting
Collecting tissue samples for lymphoma research
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
Bethesda, MarylandAges 18 years+ - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT06648889RecruitingPhase 2
Isatuximab for CD38 positive T-cell ALL
This trial tests if the drug isatuximab can help adults with a type of T-cell leukemia (T-ALL) that has come back or hasn't fully responded to treatment, or has minimal remaining disease after chemotherapy. The treatment targets a protein called CD38 found on the leukemia cells.
AugsburgAges 18 years+ - NCT02473757Enrolling by invitation
Follow-up program for adults previously treated with CAR T
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Bethesda, MarylandAges 18 years+ - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Aurora, ColoradoAges birth–38 years - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT02443831RecruitingPhase 1
CAR T-cell immunotherapy for high-risk childhood leukemia
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
LondonAges Up to 24 years - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT05620680Recruiting
CD7 CAR-T for relapsed or resistant T-cell cancers
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Shenzhen, GuangdongAges 18–75 - NCT05326243RecruitingPhase 1/Phase 2
CAR-T therapy for hard-to-treat B-cell lymphoma
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Taipei, TaiwanAges 14 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT04283006RecruitingEarly Phase 1
CAR T-cell treatment for hard-to-treat B-cell blood cancers
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hangzhou, ZhejiangAges 3–70 - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT06559189RecruitingPhase 1
A new CAR T therapy for children with relapsed B-ALL
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
Aurora, ColoradoAges 3 months–30 years - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT06732492RecruitingPhase 1
RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Wuhan, HubeiAges 3–70 - NCT05480449RecruitingPhase 1/Phase 2
Personalized CAR-T for children with high-risk B-ALL
This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.
Philadelphia, PennsylvaniaAges birth–29 years
Hear when a new T-cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t-cell leukemia?
- Yes. Clin2 currently lists 189 recruiting t-cell leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.